Corrigendum to 'Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)' [European Journal of Cancer 152 (2021) 116-128]
1 National and Kapodistrian University of Athens, Laikon Hospital, Athens, Greece. Electronic address: [email protected].
2 University Hospital Zürich Skin Cancer Center, Zürich, Switzerland.
3 Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
4 Hospital Clinic of Barcelona, Barcelona, Spain.
5 Unit of Medical Oncology, University of Perugia, Perugia, Italy.
6 National Institute of Oncology, Budapest, Hungary.
7 Eberhard Karls University, Tuebingen, Germany.
8 University Hospital Essen, Essen, Germany; German Cancer Consortium, Heidelberg, Germany.
9 University Hospital Prague and Charles University First Medical Faculty, Prague, Czech Republic.
10 Hannover Medical School, Hannover, Germany.
11 Oncology Institute of Veneto IRCCS, Padua, Italy.
12 University Hospital Centre Bordeaux, Hôpital Saint-Andre´, Bordeaux, France.
13 Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
14 University Medical Center, Mainz, Germany.
15 Division of Medical Oncology for Melanoma, Sarcoma, and Rare Tumors, IEO, European Institute of Oncology IRCCS, Milan, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy.
16 Department of Medical Oncology, Isala Oncological Center, Zwolle, Netherlands.
17 Pierre Fabre Medicament, Boulogne-Billancourt, France.
18 At Time of Research: Pfizer Inc., Boulder, CO, USA.
19 Institute Gustave Roussy, Villejuif, France.
20 Massachusetts General Hospital, Boston, MA, USA.